Skip to Main Content

Cidara Therapeutics, Inc.

CDTX Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership
Income
Balance Sheet
Cash Flow
CDTX Income Statement
CDTX Balance Sheet
CDTX Cash Flow

Recent trades of CDTX by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
CDTX Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
CDTX Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CDTX Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes by institutional investors

Quarterly net insider trading by CDTX's directors and management

Government lobbying spending instances

  • $10,000 Oct 19, 2020 Issue: Medical/Disease Research/Clinical Labs Budget/Appropriations
  • $20,000 Jul 15, 2020 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs
  • $20,000 Apr 16, 2020 Issue: Budget/Appropriations Medical/Disease Research/Clinical Labs

Estimated quarterly lobbying spending

U.S. Patents

New patents grants

  • Patent Title: Compositions and methods for the treatment of viral infections Dec. 05, 2023
  • Patent Title: Compositions and methods for the treatment of fungal infections Nov. 21, 2023
  • Patent Title: Dosing regimens for treatment of fungal infections Aug. 01, 2023
  • Patent Title: Dosing regimens for echinocandin class compounds May. 23, 2023
  • Patent Title: Synthesis of echinocandin antifungal agent Dec. 13, 2022
  • Patent Title: Compositions and methods for the treatment of viral infections Nov. 29, 2022
  • Patent Title: Compositions and methods for the treatment of fungal infections Dec. 14, 2021
  • Patent Title: Methods for preventing and treating pneumocystis infections Sep. 22, 2020
  • Patent Title: Dosing regimens for echinocandin class compounds Jul. 07, 2020
  • Patent Title: Methods for preventing and treating pneumocystis infections Aug. 06, 2019
  • Patent Title: Dosing regimens for echinocandin class compounds Jul. 10, 2018
  • Patent Title: Antifungal agents and uses thereof Jun. 13, 2017
  • Patent Title: Dosing regimens for echinocandin class compounds Dec. 27, 2016
  • Patent Title: Antifungal agents and uses thereof Dec. 22, 2015
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CDTX in WallStreetBets Daily Discussion

CDTX News

Recent insights relating to CDTX

CNBC Recommendations

Recent picks made for CDTX stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CDTX

CDTX Top Shareholders
Shareholder
Shares Held
CDTX Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CDTX Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CDTX Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top